The Legal 500 > Lenz & Staehelin > Zurich, SWITZERLAND > Lawyer profiles

Lenz & Staehelin

BRANDSCHENKESTRASSE 24, 8027 ZURICH, SWITZERLAND

Tel:: Work +41 58 450 80 00
Fax:: Fax +41 58 450 80 01

Email:

Web:: www.lenzstaehelin.com

Geneva, Lausanne, Zurich

Dr Rudolf Tschäni

Tel:: Work +41 58 450 80 00
Email:

Web:: www.lenzstaehelin.com

Profile
Lawyer Rankings

Work Department

Corporate and M&A, Public Tender Offers, Private Equity, Corporate Governance, Banking and Finance, Capital Market and Commercial Litigation and Arbitration (particularly M&A Litigation).

Position

Rudolf Tschäni is regarded as a leading expert in the market. Apart from advising on transactions generally, he concentrates on advising the board and management in takeover and stress situations as well as generally in the area of corporate governance. Furthermore, he has extensive experience as board member and is often nominated as arbitrator in national and international arbitration procedures, in particular in disputes relating to mergers and acquisitions.

Career

Admission to Zurich Bar, Admission to New York Bar, Partner at Lenz & Staehelin, since 2018 Senior Counsel at Lenz & Staehelin.

Languages

German, English, French.

Education

University of Zurich (lic. iur.), College of Europe, Brugge (H.E.E), University of Zurich (Dr. iur.), Harvard Law School (LL.M.).

Switzerland

Capital markets

Within: Capital markets

One of the 'leading practices in Switzerland', Lenz & Staehelin's 'depth and quality is world class'. Equity transactions, bond offerings, securitisation, derivatives, convertibles and structured notes are among its areas of expertise. 'Stand-out performer' Jacques Iffland advised ObsEva on a $60m private investment of shares and short-term warrants regarding a public equity transaction with several investors, while Rudolf Tschäni and Hans-Jakob Diem assisted Sika with its CHF1.65bn issuance of senior convertible bonds on SIX Swiss Exchange. 'Knowledgeable and thorough' derivatives and structured products expert François Rayroux and Zurich co-lead Patrick Schleiffer are other names to note.

[back to top]

Commercial, corporate and M&A

Within: Leading individuals

Rudolf Tschäni - Lenz & Staehelin

Within: Commercial, corporate and M&A

Lenz & Staehelin's 'highly recommended, hands-on' team stands out for its 'very thorough levels of preparation' and 'impeccable integrity', 'combining exceptional lawyers with tremendous collegiality and client service'. Focus areas include private and public M&A, corporate governance, and private equity transactions. In a recent highlight, 'world-class M&A lawyer' Hans-Jakob Diem assisted Saudi Basic Industries with its upcoming 24.99% share capital acquisition in Clariant. Rudolf Tschäni is another key practitioner, while clients further recommend 'extraordinarily smart' Tino Gaberthüel; 'committed' Beat Kühni, who has 'an encyclopaedic knowledge'; 'clear, proactive and quick' Stephan Erni; as well as 'efficient and flexible' Geneva-based Guy Vermeil.

[back to top]

Back to index

Search News and Articles

Legal Developments in Switzerland

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Bär & Karrer Successfully Assisted UEFA Before the Court of Arbitration for Sport

The proceedings concerned an appeal filed by the Albanian football club KS Skënderbeu against a decision issued by UEFA.

- BÄR & KARRER LTD.
Bär & Karrer Advises Acushnet on the Acquisition of KJUS

Acushnet Holdings Corp., the worldwide leader in the design, development, manufacture and distribution of golf equipment and wear, has announced the acquisition of KJUS, a Swiss-based ski and golf sportswear company.

- BÄR & KARRER LTD.
Bär & Karrer Advised Cembra Money Bank on the Financing of the Acquisition of cashgate

Cembra Money Bank has agreed to acquire cashgate. The purchase price for the acquisition of cashgate and the refinancing of cashgate's loan portfolio is partly backed by a bridge facility and is financed and refinanced by the sale of treasury shares (gross proceeds of CHF 112.8 million) in an accelerated bookbuilding, the placement of CHF 150 million perpetual additional Tier 1 bonds and CHF 250 million net share settled convertible bonds.

- BÄR & KARRER LTD.
Bär & Karrer Successfully Represents PNK Group Company in SCAI-Arbitration

Bär & Karrer successfully represented a company acting under the trademark of PNK Group, a major developer of industrial facilities in Russia, against a Western European concrete plant engineering and manufacturing company in a SCAI-arbitration concerning the delivery of (defective) equipment. After full-fledged proceedings including a hearing with several technical experts, the client was awarded partial rescission of the contract (as requested) with returning of certain defective equipment against refund of its cost, a substantial price reduction with regard to the rest of the equipment, as well as a contractual penalty payment and reimbursement for 75% of all legal costs. Team members were Matthew Reiter and Désirée Schreyer (both arbitration).

- BÄR & KARRER LTD.
Bär & Karrer Advises Zurich on its Investment in autoSense

Zurich Insurance Company Ltd (Zurich) invests in the Swiss start-up autoSense. Zurich will further develop autoSense's business together with Swisscom and Amag. autoSense operates a digital service portal which connects vehicles through an app and provides real-time information and services to car owners.

- BÄR & KARRER LTD.
Bär & Karrer Advises Swedish Orphan Biovitrum AB in the Acquisition of emapalumab

Swedish Orphan Biovitrum AB, an international specialty biopharmaceutical company listed in Sweden, agreed to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition supersedes the previously announced exclusive licence agreement with Novimmune. In addition, Sobi agreed with Novimmune on options for the shared financial rights to NI-1701 and NI-1801, two product candidates in the field of immuno-oncology. The transaction value is CHF 515 million, of which CHF 400 million was previously committed in the exclusive license agreement for emapalumab.

- BÄR & KARRER LTD.
Bär & Karrer Advises Patinex and BZ Bank on the Sale of NovImmune to Light Chain Bioscicence

Light Chain Bioscience AG, a Swiss biotech company, agreed to purchase all shares in NovImmune SA, a company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune related disorders and cancer. Patinex and BZ Bank are the selling majority shareholders of NovImmune.

- BÄR & KARRER LTD.
Bär & Karrer Awarded "Law Firm of the Year - Switzerland" at the Citywealth Magic Circle Awards 201

Bär & Karrer is pleased to announce that it has received the award “Law Firm of the Year - Switzerland” at the Citywealth Magic Circle Awards in London. This award recognizes Bär & Karrer as the Swiss law firm with the best private client team.

- BÄR & KARRER LTD.
Bär & Karrer Advises Ashcroft on the Acquisition of Rüeger Holding

Ashcroft Inc., headquartered in Stratford, CT, USA, a subsidiary of Tokyo Stock Exchange listed Nagano Keiki Co., Ltd, has announced the completion of the acquisition of Swiss-based Rüeger Holding SA (Rüeger) and Dutch-based STIKO Meetapparentenfabriek B.V. (Stiko), both manufacturers of specialty temperature and pressure measurement products, from their previous owners, Bernard and Jean-Marc Rüeger.

- BÄR & KARRER LTD.
Ordinance on Integrity and Transparency in the Therapeutic Products Sector has been adopted

Click here for more information.

- BÄR & KARRER LTD.

Lawyer rankings